Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Revenue (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Revenue for 10 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue fell 59.6% year-over-year to $5.4 million, compared with a TTM value of $33.0 million through Sep 2025, up 84.57%, and an annual FY2024 reading of $27.0 million, up 2796.57% over the prior year.
  • Revenue was $5.4 million for Q3 2025 at Spero Therapeutics, down from $14.2 million in the prior quarter.
  • Across five years, Revenue topped out at $15.4 million in Q4 2021 and bottomed at -$1.6 million in Q4 2023.
  • Average Revenue over 5 years is $5.3 million, with a median of $5.1 million recorded in 2021.
  • The sharpest move saw Revenue soared 9994.12% in 2021, then tumbled 111.0% in 2023.
  • Year by year, Revenue stood at $15.4 million in 2021, then fell by 4.46% to $14.8 million in 2022, then crashed by 111.0% to -$1.6 million in 2023, then soared by 562.91% to $7.5 million in 2024, then fell by 27.57% to $5.4 million in 2025.
  • Business Quant data shows Revenue for SPRO at $5.4 million in Q3 2025, $14.2 million in Q2 2025, and $5.9 million in Q1 2025.